Figure 2.

Schematic and chronological presentation of the more recent preclinical immunocompetent mouse models for glioblastoma with information about stemness, immune cell composition, the effects of standard of care and the efficiency of immunotherapy. RT: radiotherapy, TMZ: Temozolomide, Treg: regulatory T cell, DC: dendritic cell, MHC-I/II: major histocompatibility complex I or II, TAM: tumor associated macrophage, (+) presence of stem cell populations and/or positive effect of treatment administration, (−) no effect of treatment administration, (?) data not available in literature and (*) resistance to immune checkpoint blockade.